Impact of Angiotensin II Receptor Blocker Therapy (Olmesartan or Valsartan) on Coronary Atherosclerotic Plaque Volume Measured by Intravascular Ultrasound in Patients With Stable Angina Pectoris

详细信息    查看全文

• 作者：Hideki Ishii ; Masakazu Kobayashi ; Nobutake Kurebayashi ; Daiji Yoshikawa ; Susumu Suzuki ; Satoshi Ichimiya ; Masaaki Kanashiro ; Takahito Sone ; Hideyuki Tsuboi ; Tetsuya Amano ; Tadayuki Uetani ; Ken Harada ; Nobuyuki Marui ; Toyoaki Murohara
• 刊名：The American Journal of Cardiology
• 出版年：2013
• 出版时间：1 August, 2013
• 年：2013
• 卷：112
• 期：3
• 页码：363-368
• 全文大小：181 K

文摘

Coronary plaques can be reduced by some medications. The aim of this study was to compare the effects of 2 angiotensin II receptor blockers (olmesartan at 20 mg/day or valsartan at 80 mg/day) on coronary plaque by coronary intravascular ultrasound. One hundred hypertensive patients with stable angina pectoris who underwent elective percutaneous coronary intervention were randomly selected to receive 1 of the 2 angiotensin II receptor blockers after coronary intervention. Nontarget coronary lesions with mild to moderate stenosis were measured by volumetric intravascular ultrasound at baseline and after 6 months. After 6 months, both the olmesartan and the valsartan groups showed significant reduction of the examined coronary plaque volume (46.2 ¡À 24.1 mm³ at baseline vs 41.6 ¡À 21.1 mm³ at 6 months: 4.7 % decrease, p?= 0.0002; and 47.2 ¡À 32.7 mm³ at baseline vs 42.5 ¡À 30.2 mm³ at 6 months: 4.8 % decrease, p?= 0.002, respectively). There was no statistically significant difference of plaque regression between the 2 groups (p?= 0.96). In conclusion, there was a significant decrease from baseline in the coronary plaque volume in patients with stable angina pectoris who received olmesartan or valsartan for 6 months. In addition, there was no significant difference in the reduction of plaque volume achieved by these 2 medications.